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 Abstract 
  Background/Aims:   Anti-glomerular basement membrane (GBM) nephritis is characterized by ac-
tivation of the renin-angiotensin system. This study aimed to determine the question of whether 
a temporary angiotensin II blockade at the initial stage of anti-GBM nephritis is able to attenuate 
the disease as well as differences in renoprotection among angiotensin II receptor blockers (ARBs) 
with distinct peroxisome proliferator-activated receptor (PPAR)-  -modulating activities.  Methods:  
C57BL/6J mice were immunized with rabbit IgG, followed by intravenous injection of rabbit anti-
mouse antibodies. Mice were then treated with telmisartan, losartan, and telmisartan + GW9662 
(a PPAR-     antagonist) for 5 days, or hydralazine for 9 days. On days 8 and 13, mice were sacrificed 
to obtain tissues for histological analysis.   Results:   The temporary administration of telmisartan 
significantly suppressed glomerular damage compared to hydralazine. Losartan showed a similar 
effect but was less effective. Co-administration of GW9662 attenuated the renoprotective effect 
of telmisartan, almost to levels observed with losartan. In particular, it limited the decreased infil-
tration of inflammatory cells and preservation of capillaries in the glomeruli induced by telmisar-
tan.   Conclusion:   Temporary angiotensin II blockade at the initial stage of anti-GBM disease dra-
matically inhibited its progression. In addition to a class effect of ARBs, telmisartan modified 
inflammation and endothelial damage in the kidney through its PPAR-   -agonistic  action. 
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 Introduction 
  Anti-glomerular basement membrane (GBM) nephritis has been most widely studied 
experimentally as a representative of immune-mediated renal diseases. Anti-GBM disease is 
characterized by damage to the GBM followed by the invasion of inflammatory cells such as 
neutrophils, macrophages and CD8+ T cells and the destruction of the glomerular capillary 
network, culminating in glomerular sclerosis   [1, 2]  . Monocyte chemoattractant protein-1 
(MCP-1) has been demonstrated to be a dominant chemokine involved in macrophages/
monocytes in anti-GBM nephritis   [3, 4]  .
  The activation of the renin-angiotensin system (RAS) and increases in glomerular MCP-
1 levels were detected at an early stage of anti-GBM nephritis   [5]  . The glomerular damage 
and MCP-1 expression were dramatically reduced in the kidneys of angiotensin II type 1 re-
ceptor (AT  1  R)-deficient mice. This suggested that RAS activation plays a critical role in in-
flammation during anti-GBM disease  [5] . The clinical benefits of angiotensin receptor block-
ers (ARBs) have been well established in chronic kidney disease patients with diabetic and 
non-diabetic nephropathies  [6, 7] . However, whether ARBs would be effective in suppressing 
acute onset of inflammatory disorders in the kidney remains to be determined.
    In 1995, Lehmann et al.   [8]   discovered that peroxisome proliferator-activated receptor 
(PPAR)-     is the intracellular high-affinity receptor for the insulin-sensitizing and anti-dia-
betic thiazolidinediones, the activation of which blocked adipogenesis and differentiation 
into mature adipocytes. Ligand activation of PPAR-     also downregulated the transcription 
of genes encoding inflammatory cytokines, growth factors, proteolytic enzymes, adhesion 
molecules, chemokines and atherogenic factors   [9, 10]  . Among many ARBs, telmisartan has 
been shown to constitute a unique subset of AT  1   blockers capable of activating intracellular 
PPAR-    . In contrast, losartan is another ARB but with little PPAR-     activity   [11]  .
    In this study, we demonstrated in a mouse model that the progression of anti-GBM dis-
ease was significantly inhibited by temporary administration of telmisartan or losartan at 
an early stage. Moreover, telmisartan provided additional therapeutic benefits by suppress-
ing glomerular inflammation and endothelial injury through its PPAR-   -mediated  effects. 
With respect to renoprotection, losartan was less effective than telmisartan. Therefore, it is 
conceivable that the early administration of telmisartan could be an effective treatment op-
tion for patients with immune-mediated renal damage.
  M e t h o d s  
  Mice and Reagents 
  Eight-week-old, female C57BL/6J mice were purchased from Japan SLC, Inc. (Shizuoka, 
Japan). All studies were reviewed and approved by the Animal Care and Use Committee of 
Chiba University. Telmisartan and losartan were kindly provided by Nippon Boehringer In-
gelheim Co. and MSD K.K. (Tokyo, Japan), respectively. GW9662, a PPAR-   antagonist, was 
purchased from Sigma (St. Louis, Mo., USA).
    Induction of Accelerated Anti-GBM Glomerulonephritis 
  Rabbit anti-GBM antiserum was prepared as previously described   [12]  . The C57BL/6J 
mice were immunized subcutaneously with 250   g of normal rabbit IgG in complete Freund’s 
adjuvant. This was followed by intravenous injections of a total of 120     l of nephrotoxic se-
rum 5 and 6 days later which, for purposes of experimental treatment, were considered as 
days 0 and 1. Mice were treated with telmisartan (15 mg/kg/day, i.p.), losartan (20 mg/kg/
day, i.p.), telmisartan + GW9662 (1, 3 or 10 mg/kg/day, i.p.) for 5 days (days 0–4), or hydral-80
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azine from Sigma (4 mg/kg/day, i.p.), to normalize blood pressure to the same levels that were 
seen in the telmisartan and losartan groups, for 9 days (days 0–8) after the first injection of 
the anti-GBM antibodies. On days 4 and 8, blood pressure was measured using a sphygmo-
manometer (BP-98A; Softron, Tokyo, Japan). On days 8 and 13, serum and urine samples 
were collected to evaluate renal function, and mice were sacrificed to obtain tissues for his-
tological study. Levels of blood urea nitrogen (BUN), serum creatinine (S  Cr  ) levels and uri-
nary albumin excretion (UAE) were determined as previously described  [12] . Three indepen-
dent experiments were performed and representative data are shown in   figures 1–7  .
  Histological  Analysis 
  Morphologic changes in the glomeruli or tubulointerstitial areas were scored on a scale 
from 0 to 5: 0, none of the glomeruli or no tubulointerstitial area was affected by morpho-
logic changes; 1,   !  20%; 2,   !  40%; 3,   !  60%; 4,   !  80%, and 5, 100% affected. In the analysis of 
glo  meruli, scores were assigned separately for intraglomerular cell proliferation, glomerular 
thrombosis, and extracapillary cellular proliferation (crescent formation). The sum of the 
three scores was used in the analysis of glomeruli. For the interstitium, separate scores were 
assigned for infiltration of mononuclear cells, damage of tubules, and interstitial fibrosis, 
and the sum of the three scores was used for analysis. Semiquantitative analysis was per-
formed as described previously  [12] . The scoring was performed by two independent observ-
ers on blinded sections.
    Immunohistochemistry and Apoptosis Assay 
  Immunohistochemical staining was performed as described previously   [12]  . For prima-
ry antibodies, rat anti-mouse CD31 (BD PharMingen, San Diego, Calif., USA), rat anti-mouse 
neutrophil (clone 7/4; Immunotech, Praha, Czech Republic), rat anti-mouse CD11b (BD 
PharMingen), or rat anti-mouse CD8a antibodies (BD PharMingen) were used. Apoptotic 
nuclei were detected as described previously   [13]  .
    Real-Time Reverse Transcription-Polymerase Chain Reaction  
  RT-PCR was performed as described previously   [12]  . The following gene-specific prim-
ers were used: MCP-1 – (forward) GCA TCC ACG TGT TGG CTC A and (reverse) CTC CAG 
CCT ACT CAT TGG GAT CA; vascular endothelial growth factor (VEGF) – (forward) CTG 
GAT ATG TTT GAC TGC TGT GGA and (reverse) GTT TCT GGA AGT GAG CCA ATG 
TG, and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) – (forward) ATG GGG TGA 
GGC CGG TGC TG and (reverse) CTT GAT GTC ATC ATA CTT GG.
  Statistical  Analysis 
 The number of mice used for each experiment is indicated in the figure legends. Statisti-
cal analyses were performed using ANOVA. As needed, additional analysis was carried out 
using the t test with Bonferroni correction to identify significant differences. A value of p  !  
0.05 was considered to be statistically significant. The results are shown as means   8   SE.
  R e s u l t s  
  After induction of anti-GBM disease, administering telmisartan or losartan for 5 days 
resulted in a significant inhibition on day 8 of the hydralazine effect of elevating UAE and 
S  Cr  levels ( fig. 1 a–c). In addition, on day 13 the increase of BUN and S  Cr  levels seen in hydral-
azine-treated mice was suppressed only in the mice treated with telmisartan ( fig. 1 b, c). Nine-
day treatment with hydralazine had no effect on the progression of anti-GBM disease ( fig. 1 b, 81
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  Fig. 1.  UAE (  a ), BUN (  b ), S Cr  ( c ) and blood pressure (BP;   d ) were estimated in normal mice (n = 5), nephrit-
ic mice without treatment (No Tx, n = 10) and those treated with hydralazine (Hyd, n = 10), telmisartan 
(Tel, n = 10) or losartan (Los, n = 10).   *  p   !   0.05,   *  *  p   !   0.01, vs. hydralazine;   a   p   !   0.05,   b  p   !   0.01, vs. telmi-
sartan. 82
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  Fig. 2.   Normal and nephritic kidneys (  a ,   b  ) were stained with periodic acid-Schiff (PAS) reagents. Total 
glomerular (  c  ) and tubulointerstitial (  d  ) scores were estimated as described in the Methods section. The 
induction of anti-GBM nephritis in mice without treatment (No Tx) or hydralazine (Hyd)-treated mice 
contributed significantly to severe glomerular damage including glomerular proliferation (yellow arrow-
head), thrombosis (black arrowheads) and crescent formation (white arrowheads), which was attenuated 
by telmisartan (Tel) or losartan (Los).   *  p   !   0.05,   *  *  p   !   0.01, vs. hydralazine,   a  p   !   0.05,   b  p   !   0.01, vs. 
telmisartan. 83
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c,   2  c, d). There was no difference in mean blood pressures among all groups on days 4 and 8 
( fig. 1 d).
    Nephritic mice, whether treated or not treated with hydralazine, showed glomerular 
cell proliferation, thrombosis and crescent formation on days 8 and 13 (  fig. 2  a, b). Telmi-
sartan or losartan administration significantly reduced the total glomerular score (com-
posed of cell proliferation, thrombosis and crescent formation) on day 8. The total score for 
the tubulointerstitium was decreased only in telmisartan-treated mice on day 8. Interest-
ingly, for day 13 only telmisartan showed improvements in the glomerular and interstitial 
scores (  fig. 2  a–d). The administration of hydralazine, telmisartan or losartan did not affect 
deposition on the GBM of heterologous or autologous antibodies and complement on day 
8, as assessed by the binding of rabbit anti-GBM antibody, mouse IgG and C3, respectively 
( fig. 3 ).
  To explore how telmisartan provides renoprotection during anti-GBM disease, the PPAR-
    -modulating activity of telmisartan was examined   [11]  . Blocking of PPAR-     activity with 
GW9662 attenuated the telmisartan-mediated decrease in UAE, BUN and S  Cr   levels on day 8. 
In mice treated with a high dosage of GW9662, UAE and S  Cr   levels were similar to those in 
mice administered losartan with minimal PPAR-   -modulating  activity  ( fig. 1 a–c,   4 a–c).  The 
injection of a high dosage of GW9662 into normal mice had no effect on UAE and renal func-
  Fig. 3.   Representative immunofluorescence staining for deposition of rabbit IgG, mouse IgG and C3 on 
glomeruli of hydralazine (Hyd)-, telmisartan (Tel)- or losartan (Los)-treated nephritic mice. 84
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tion ( fig. 4 a–c; GW Only). The glomeruli from the mice injected a high dosage of GW9662 were 
enlarged with extensive thrombosis (black arrowheads) on day 8 (  fig. 4  d; GW High). Consis-
tent with renal function, co-administration of a high dosage of GW9662 led to increased total 
scores for glomeruli and interstitium in a dose-dependent manner ( fig. 4 e, f; GW High). There 
was no difference in the amount of rabbit anti-GBM antibody, mouse IgG and C3 deposited 
along the GBM among GW9662-treated and other mouse groups (data not shown).
    Glomerular infiltration of polymorphonuclear leukocytes, macrophages/monocytes and 
CD8+ T cells and MCP-1 expression were significantly increased over normal levels in hy-
dralazine-treated mice on day 8 during anti-GBM disease. Telmisartan inhibited these effects 
of hydralazine (  fig. 5  ). In the hydralazine-treated mice, the decrease in VEGF expression 
  Fig. 4.   UAE (  a  ), BUN (  b  ) and S  Cr   ( c  ) were estimated in normal mice (n = 5), normal mice injected 10 mg/
kg/day GW9662 (GW Only, n = 5), nephritic mice without treatment (No Tx, n = 10) and those treated 
with hydralazine (Hyd, n = 10), telmisartan (Tel, n = 10), telmisartan + 1 mg/kg/day GW9662 (GW Low, 
n = 5), telmisartan + 3 mg/kg/day GW9662 (GW Mid, n = 5) or telmisartan + 10 mg/kg/day GW9662 (GW 
High, n = 6). Co-administration of GW9662 abrogated the improved renal function observed in telmis-
artan-treated mice in a dose-dependent manner.   *  p   !   0.05,   *  *  p   !   0.01, vs. hydralazine,   a  p   !   0.05, vs. 
telmisartan. 85
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  Fig. 4.   Kidney sections (PAS;   d  ) and total glomerular (  e  ) and tubulointerstitial (  f  ) scores were estimated 
in normal mice (n = 5), normal mice injected 10 mg/kg/day GW9662 (GW Only, n = 5), nephritic mice 
without treatment (No Tx, n = 10) and those treated with hydralazine (Hyd, n = 10), telmisartan (Tel, n = 
10), telmisartan + 1 mg/kg/day GW9662 (GW Low, n = 5), telmisartan + 3 mg/kg/day GW9662 (GW Mid,
n = 5) or telmisartan + 10 mg/kg/day GW9662 (GW High, n = 6). Co-administration of GW9662 abro-
gated the improved histopathological findings observed in telmisartan-treated mice in a dose-dependent 
manner. The yellow, black and white arrowheads indicate glomerular proliferation, thrombosis and cres-
cent formation, respectively.   *  p   !   0.05,   *  *  p   !   0.01, vs. hydralazine,   a  p   !   0.05,   b  p   !   0.01, vs. telmisartan. 86
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  Fig. 5.   Kidney sections from hydralazine (Hyd)-, telmisartan (Tel)- or telmisartan + 10 mg/kg/day 
GW9662 (GW High)-treated nephritic mice were stained with antibodies against polymorphonuclear 
leukocytes (PMN;   a  ), macrophages/monocytes (M/Mo;   b  ) and CD8+ cells (  c  ). Sections were counter-
stained with Mayer’s hematoxylin.   d   MCP-1 mRNA expression in the cortex of telmisartan- compared 
with hydralazine-treated mice was significantly decreased and was increased again by the addition of 
GW9662.   *  *  p   !   0.01, vs. hydralazine.   a   p   !   0.05,   b   p   !   0.01, vs. telmisartan. 87
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along with the density of glomerular capillaries was reversed by telmisartan, and to a lesser 
extent by GW High ( fig. 6 ). The number of glomerular apoptotic cells was increased over nor-
mal levels on day 8. This increase was significantly inhibited by telmisartan (  fig. 7  ). In sum-
marizing these observations, glomerular inflammation, endothelial damage and apo  ptosis 
were dramatically suppressed by temporary administration of telmisartan at the initial stage 
of anti-GBM disease, which was also reversed by co-administration of GW9662 (  fig. 5–7  ).
  Fig. 6.    a   Mice without treatment (No Tx) or hydralazine-treated (Hyd) nephritic mice showed reduction 
of glomerular capillaries compared with normal mice. This was significantly abrogated by telmisartan, 
and to a lesser extent by co-administration of 10 mg/kg/day GW9662 (GW High). Representative staining 
is shown.   b  VEGF mRNA expression in the cortex was consistent with the density of glomerular capillar-
ies.   *  p   !   0.05,   *  *  p   !   0.01, vs. hydralazine,   a   p   !   0.05, vs. telmisartan. 
  Fig. 7.   Telmisartan (Tel) reduced the number of TUNEL-positive cells in the glomeruli, which was pre-
vented by co-administration of 10 mg/kg/day GW9662 (GW High). Representative staining is shown. 
  *  *  p   !   0.01, vs. hydralazine.   a  p   !     0.05, vs. telmisartan. 88
Nephron Extra 2011;1:78–90
 DOI:  10.1159/000331704 
EXTRA
  Hamano et al.: PPAR-     and Anti-GBM Disease 
www.karger.com/nne
    © 2011 S. Karger AG, Basel
  Published online: September 22, 2011 
  Discussion 
  Angiotensin II blockade applied at the initial stage of anti-GBM disease in mice signifi-
cantly inhibited its progression as determined on days 8 and 13. Since the levels of antibodies 
in the GBM, complement and blood pressure were similar among telmisartan-, losartan- and 
hydralazine-treated mice, marked amelioration of renal injuries in ARB-treated mice is not 
believed to be due to differences in antibody production, complement activation and blood 
pressure. The deposition of anti-GBM antibodies in the GBM initiates the release of renin 
and angiotensinogen, and robust RAS activation occurs within 24 h after the induction of 
anti-GBM disease   [5, 14]  . Angiotensin II is also a potent inducer of MCP-1 and pro-inflam-
matory cytokines, and numerous studies suggest that MCP-1 plays an important role in the 
progression of anti-GBM disease with irreversible damage  [5, 15] . In previous studies, block-
ade of the angiotensin II cascade on inflammatory and/or resident cells inhibited glomerular 
inflammation by decreasing pro-inflammatory mediators such as MCP-1, TNF-    , IL-6 and 
regulating the differentiation and activation of M1 and M2 macrophages   [15, 16]  . This may 
be relevant to the observations in our present study in which the temporary blockade of AT  1 R 
at an early stage dramatically suppressed glomerular inflammation.
    This study showed that telmisartan was significantly more effective than losartan in 
blocking the progression of anti-GBM disease. Moreover, this dramatic effect of telmisartan 
was due to its temporary blockade of angiotensin II when used at the initial stage of anti-
GBM disease. A possible explanation is that the half-life of telmisartan is approximately 
24 h while that of losartan and the active metabolite, EXP3174, is 2.1 and 6.3 h, respectively 
 [17] . However, the ARBs exhibited the same degree of blood pressure lowering on days 4 and 
8. Alternatively, there may be a difference in lipophilicity between telmisartan and losartan 
  [18]  . Telmisartan is the ARB with the highest lipophilicity and penetrates easily into the tis-
sues or cells in contrast to EXP3174 with the lowest lipophilicity. Takai et al.   [18]   suggested 
that the lipophilicity of telmisartan reduces oxidative stress in vascular tissues and protects 
vascular function in stroke-prone spontaneously hypertensive rats. Thus, telmisartan may 
preserve the glomerular and interstitial capillaries and suppress the progression of glomeru-
lar sclerosis more efficiently than losartan during anti-GBM nephritis.
  It is known that telmisartan exhibits the highest PPAR-   agonistic activity among ARBs 
 [11] . Our results using GW9662 clearly showed that PPAR-   activity in telmisartan inhibited 
the progression of anti-GBM disease in mice. Interestingly, the renal injuries of telmisartan-
treated mice given PPAR-     inhibitor were almost similar to those of losartan-treated mice. 
This suggests that the difference between telmisartan and losartan applied during anti-GBM 
disease may be associated with PPAR-     agonistic activity.
    Furthermore, glomerular inflammation and capillary reduction were significantly in-
hibited by the agonistic property of PPAR-   .  PPAR-    agonists exert anti-inflammatory ef-
fects in numerous disease models, including atherosclerosis and inflammatory bowel disease 
  [19]  , and also exert anti-inflammatory effects in human subjects with type 2 diabetes   [10]  . 
PPAR     is expressed in macrophages and inhibits a subset of inflammatory responsive genes 
in macrophages, including MCP-1, TNF-     and IL-1       [19]  . The deletion of PPAR-     from 
macrophages results in more severe diet-induced insulin resistance, suggesting that the adi-
pose tissue macrophages are major sources of pro-inflammatory mediators that induce an 
insulin-resistant state and PPAR-     functions in part as a negative regulator of macrophage 
activation   [20] .
    This study showed that PPAR-     agonistic action significantly induced neoangiogenesis 
and elevated VEGF expression during anti-GBM disease. Although angiogenic potentials of 
PPAR-    agonists have been intensively investigated, it remains to be established whether they 
are angiogenic or anti-angiogenic. Nonetheless, the selective PPAR-     activation resulted in 89
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neoangiogenesis of mouse cornea through the upregulation of VEGF   [21]  . Moreover, tumor 
growth was enhanced in mice implanted with tumor cells with constitutively active PPAR-  , 
which was associated with increased angiogenic factors such as angiopoietin-like 4, VEGF 
and fibroblast growth factors 1 and 9  [22] . Rosiglitazone ameliorated endothelial dysfunction 
in type 2 diabetes patients and increased the number and migratory activity of endothelial 
progenitor cells   [21, 23]  . This may be related to the upregulation of VEGF since it increases 
vascular permeability and contributes to the development of edema, which is also a common 
side effect of thiazolidinediones   [24]  .
  In conclusion, we demonstrated that the temporary administration of telmisartan at the 
initial stage of anti-GBM disease significantly inhibited its progression. Losartan showed a 
similar effect but was less effective. Telmisartan provided additional therapeutic benefits by 
suppressing glomerular inflammation and endothelial injury through its PPAR-   -mediated 
effects. These findings present new information to understand the biological and therapeutic 
effects of telmisartan with a potentially important implication for the management of pa-
tients with immune-mediated renal damage.
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